Can Furosemide Cause Ototoxicity? Signs and Risks

Furosemide, one of the most widely prescribed loop diuretics in the world, can cause ototoxicity, and its potential to trigger tinnitus and hearing loss was recognized shortly after the drug entered clinical use in the 1960s. The damage is usually temporary, but permanent hearing loss has been documented, particularly when the drug is given intravenously at high doses or alongside other ear-toxic medications.¹ What makes furosemide ototoxicity a genuinely tricky clinical problem is that the people who need the drug most urgently, such as those in heart failure or kidney failure, are often the same people whose bodies handle it in ways that raise the risk of ear damage.

How Furosemide Damages the Inner Ear

Furosemide targets a specific ion transporter in the kidneys to pull excess fluid from the body. That same transporter exists in the inner ear, in a tissue called the stria vascularis, which is responsible for maintaining the unique chemical environment that allows you to hear. When furosemide reaches the stria vascularis, it disrupts the delicate balance of ions in the fluid-filled compartment of the cochlea. The drug inhibits the sodium-potassium-chloride cotransporter there, interferes with key enzymes, and causes fluid-filled swelling (edema) in the tissue lining. This leads to a rapid drop in the electrical charge that drives hearing, called the endolymphatic potential.²

More recent research has added another layer: one of the earliest effects of furosemide in the inner ear is a dramatic reduction in blood flow to the lateral wall of the cochlea.² So the damage is not purely chemical. The drug also chokes off the blood supply that keeps the stria vascularis functioning, which compounds the direct ion-transport disruption. The swelling in the stria vascularis has been shown in animal studies to be reversible once the drug clears the system, which helps explain why most cases of furosemide-related hearing loss recover on their own.³

Signs and Symptoms

Furosemide ototoxicity typically shows up in one or more of three ways: tinnitus (ringing or buzzing in the ears), hearing loss, and vertigo or dizziness.¹ The onset is usually fast, often within minutes to hours of an intravenous dose, which distinguishes it from the slow-onset hearing loss caused by drugs like aminoglycoside antibiotics or platinum-based chemotherapy agents that accumulate over days or weeks. Tinnitus is frequently the first warning sign, and if the drug is stopped or the dose is reduced at that point, hearing often returns to normal.

The hearing loss itself tends to affect a broad range of frequencies rather than selectively hitting only the high-pitched sounds, which again sets it apart from some other drug-related hearing problems. In most cases it is sensorineural, meaning it involves the inner ear’s sensory apparatus rather than the mechanical structures of the middle ear. When furosemide is the only offending agent and the dose was not extreme, recovery usually happens within hours to days. But permanent hearing loss has been documented, particularly in patients with kidney failure or those receiving very high doses repeatedly.⁴

Why Route and Speed of Administration Matter So Much

The single biggest factor determining whether furosemide causes ear trouble is how quickly it reaches high concentrations in your blood. Intravenous bolus injection, where a large dose is pushed rapidly through a vein, is the scenario most commonly linked to hearing loss in humans.⁴ A study of patients with severe heart failure receiving high-dose furosemide found that hearing loss occurred only after bolus injections and not when the same total daily dose was delivered as a slow continuous drip. All five patients who developed hearing loss from bolus injection recovered fully once the drug was stopped.⁵

This makes intuitive sense given the mechanism. A rapid spike in blood levels sends a surge of unbound furosemide into the cochlea all at once, overwhelming the stria vascularis. A slow infusion delivers the same amount of drug, but the peak concentration at any given moment is lower, giving the inner ear less of a hit. For this reason, many hospital protocols now recommend infusing furosemide over at least two minutes when giving it intravenously, and using continuous infusion rather than repeated large boluses when high daily doses are needed.

Oral furosemide at typical doses presents a very different risk profile. A large study following tens of thousands of women over many years found that furosemide use was not significantly associated with increased hearing loss risk compared to women not taking blood-pressure medications. The relative risk was essentially 1.0.⁴ This does not mean oral furosemide can never harm hearing, since case reports of oral-dose ototoxicity exist, but the risk at standard oral doses in otherwise healthy patients appears to be quite low.

The Albumin Connection

One of the less intuitive risk factors for furosemide ototoxicity is how much albumin you have in your blood. Furosemide binds tightly to albumin, the most abundant protein in blood plasma. Only the unbound fraction of the drug is free to cross into tissues and exert its effects, including its ototoxic effects. When albumin levels are low, a larger share of each dose floats free in the bloodstream and reaches the cochlea.

Animal research has demonstrated this relationship vividly. Rats bred to lack albumin entirely showed ototoxic responses to furosemide at roughly half the dose needed to produce the same effect in normal rats.⁶ In another experiment, when albumin was added back intravenously alongside furosemide, the drop in the inner ear’s electrical potential was dramatically reduced, falling from over 100 millivolts of depression to single digits at higher albumin doses.⁷ Rats completely lacking albumin showed reductions in the endolymphatic potential that were an order of magnitude greater than what normal rats experienced, and giving them albumin beforehand significantly reduced the damage.⁸

This has real clinical implications. Patients with advanced kidney disease, liver disease, severe malnutrition, or nephrotic syndrome often have critically low albumin levels. These are exactly the patients who tend to need aggressive diuretic therapy. For them, the usual dose-response expectations go out the window: a dose that would be well tolerated in someone with normal protein levels can deliver far more unbound drug to the inner ear.

Dangerous Drug Combinations

Furosemide ototoxicity becomes a much more serious concern when the drug is given alongside certain other ear-toxic medications. Two classes of drugs stand out: aminoglycoside antibiotics and platinum-based chemotherapy agents.

Aminoglycosides

Aminoglycoside antibiotics like gentamicin and tobramycin are known to damage inner ear hair cells on their own. When furosemide is added, the risk climbs. The proposed explanation is that the aminoglycoside first damages the cell membranes in the inner ear, increasing their permeability. This theoretically allows the loop diuretic to penetrate into cells in higher concentrations, compounding the damage.⁹ The timing matters: giving furosemide after an aminoglycoside has already begun damaging the inner ear appears to be especially harmful. This interaction is well enough established that labeling for both drug classes warns against the combination.

Cisplatin and Other Platinum Agents

The interaction between furosemide and cisplatin, a widely used chemotherapy drug, is particularly devastating. In mice, co-administering cisplatin and furosemide caused rapid, massive hair cell loss in the cochlea, with hearing threshold shifts that climbed steeply as the cisplatin dose increased.¹⁰ Guinea pig studies showed that the ototoxic interaction was most severe when cisplatin was given at the moment the stria vascularis was most disrupted by furosemide, confirming that the diuretic essentially opens a window of vulnerability in the cochlea.¹¹

Human data backs this up. A study of over 450 childhood cancer survivors treated with platinum chemotherapy found that co-treatment with furosemide was independently associated with roughly double the odds of ototoxicity, even after adjusting for the cisplatin dose and the child’s age at diagnosis.¹² This is a finding that matters for clinical practice: furosemide is sometimes given to manage fluid retention caused by chemotherapy, and oncologists need to weigh the diuretic benefit against the increased risk of permanent hearing damage.

Premature Infants

Furosemide is commonly used in neonatal intensive care units to manage fluid overload in premature babies, particularly those with lung disease. These infants also happen to have immature inner ears and often low albumin levels, which raises the theoretical concern that they might be especially vulnerable to ototoxicity. The drug’s labeling and clinical guidelines list preterm neonates as a high-risk group.¹³

The actual evidence, however, is surprisingly thin. A retrospective review of NICU graduates found essentially identical rates of abnormal hearing screens in babies who received furosemide and those who did not, at about 15-16% in both groups.¹⁴ Another study that used matched groups to isolate furosemide’s effect found only a small, statistically non-significant increase in hearing screen failure among exposed infants.¹⁵ A systematic review that pulled together the available studies concluded that there was no clear evidence furosemide increases the risk of sensorineural hearing loss in premature infants, though it noted the quality of the studies was generally low and confounding was poorly controlled.¹⁶

The difficulty here is that premature infants who need furosemide are usually quite sick, and their underlying conditions, along with other medications they receive (including aminoglycosides), also carry ototoxic potential. Separating the drug’s contribution from everything else going on is genuinely hard with the study designs available. The honest summary is that the theoretical risk is real, but the published evidence has not been able to confirm that furosemide alone is a major driver of hearing loss in this population.

Who Is Most at Risk

Pulling the risk factors together, furosemide ototoxicity is most likely to occur in a recognizable set of circumstances. People at elevated risk include:

Kidney impairment: Reduced ability to clear furosemide from the body means higher and longer-lasting blood levels. Patients with renal failure are a classic high-risk group.
Low albumin: Liver disease, nephrotic syndrome, severe malnutrition, and critical illness all lower albumin, leaving more unbound furosemide circulating freely.
High or frequent doses: The ototoxic effect is dose-dependent. Patients requiring aggressive diuresis, particularly those in acute heart or kidney failure, receive doses that push toward the danger zone.
Rapid IV injection: Bolus dosing creates higher peak concentrations in the blood than oral dosing or slow infusion.
Concurrent ototoxic drugs: Aminoglycosides and platinum chemotherapy agents synergize with furosemide to damage the cochlea far more than either drug alone.
Very young age: Neonates, particularly premature infants, are considered higher risk due to immature renal function, low protein levels, and developing auditory systems.

A patient who checks multiple boxes, say a premature infant on both gentamicin and furosemide, or a patient with kidney failure receiving high-dose IV furosemide alongside cisplatin, faces a compound risk that is qualitatively different from the average person taking an oral furosemide pill for mild fluid retention.

How Furosemide Compares to Other Loop Diuretics

Furosemide is not the only loop diuretic with ototoxic potential. Bumetanide and ethacrynic acid share the same basic mechanism in the inner ear. Of the three, ethacrynic acid has historically been considered the most ototoxic, and furosemide the least on a potency-adjusted basis. Bumetanide sits in between. On a milligram-for-milligram basis, bumetanide is about five times more ototoxic than furosemide. But because bumetanide is also far more potent as a diuretic, the doses used clinically are much smaller. When adjusted for equivalent diuretic effect, bumetanide’s ototoxic potential comes out to roughly one-eighth that of furosemide.¹⁷

This comparison is a useful reminder that ototoxicity from loop diuretics is not unique to furosemide. It is a class effect tied to the mechanism these drugs share. In practice, though, furosemide’s ototoxicity gets the most attention because furosemide is by far the most commonly prescribed loop diuretic worldwide and is more likely to be given in the high-dose intravenous settings where ear damage is most likely to occur.

Monitoring and Reducing Risk

For patients who need furosemide in high-risk settings, several practical strategies can reduce the chances of hearing damage. Slowing the infusion rate is one of the simplest and best-supported interventions: as noted earlier, continuous infusion avoids the blood-level spikes that drive ototoxicity while actually delivering better diuretic results in severe heart failure.⁵ Checking albumin levels before starting aggressive IV furosemide helps identify patients whose unbound drug fraction will be disproportionately high. In those patients, adjusting the dose downward, choosing an alternative diuretic, or considering albumin co-infusion are all strategies that have physiological rationale.

Avoiding unnecessary overlap with aminoglycosides and platinum agents is another straightforward measure. When the combination cannot be avoided, separating the timing of administration and monitoring hearing before and during treatment can catch damage early. Otoacoustic emission testing, which uses a tiny microphone in the ear canal to detect sounds generated by functioning hair cells, has been studied as a non-invasive way to track cochlear health during furosemide administration. Research in animals has shown that distortion-product otoacoustic emissions closely track changes in cochlear function caused by furosemide, especially at low to moderate stimulus levels.¹⁸ In clinical practice, audiometry and otoacoustic emission testing are used in oncology and neonatology settings for patients on ototoxic drug regimens, though standardized monitoring protocols specifically for furosemide in isolation remain less common than those for aminoglycosides or cisplatin.

Furosemide’s Other Inner Ear Role in Ménière’s Disease

Interestingly, furosemide’s effect on the inner ear is not always unwanted. In the diagnosis of Ménière’s disease, a condition involving excess fluid pressure in the inner ear, doctors sometimes exploit furosemide’s ability to alter inner ear fluid dynamics as a diagnostic tool. The furosemide-loading vestibular evoked myogenic potential test works by giving furosemide and then measuring whether the electrical responses from the inner ear’s balance organs change in a way that suggests abnormal fluid buildup. Research has shown that this test can be negative in patients who have had recent vertigo attacks, likely because ruptures in the inner ear membranes during those attacks allow the fluid compartments to communicate in ways that prevent furosemide from producing its expected effect on the test.¹⁹ The same drug that clinicians worry about as a cause of hearing damage is, in a different context, used precisely because of its inner ear effects, albeit at lower doses and under controlled conditions.

1
Hospital Pharmacy. Acute Sensorineural Hearing Loss: Furosemide Ototoxicity Revisited
2
PubMed Central. Ototoxic effects and mechanisms of loop diuretics
3
Hearing Research. Effects of organic acids on the edema of the stria vascularis induced by furosemide
4
PubMed Central. Hypertension, Diuretic Use, and Risk of Hearing Loss
5
PubMed. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion
6
PubMed. Dose-response relationships for furosemide ototoxicity in rat
7
JAMA Otolaryngology–Head & Neck Surgery. Effect of Albumin-Bound Furosemide on the Endocochlear Potential of the Chinchilla: Alleviation of Furosemide-Induced Ototoxicity
8
JAMA Otolaryngology–Head & Neck Surgery. Furosemide Ototoxicity Is Enhanced in Analbuminemic Rats
9
PubMed. Ototoxicity induced by gentamicin and furosemide
10
PubMed Central. Co-administration of Cisplatin and Furosemide Causes Rapid and Massive Loss of Cochlear Hair Cells in Mice
11
Hearing Research. The combined effect of cisplatin and furosemide on hearing function in guinea pigs
12
PubMed. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study
13
The Lancet. Furosemide ototoxicity and diuretic renography
14
PubMed. Use of furosemide and hearing loss in neonatal intensive care survivors
15
PubMed Central. Prolonged Furosemide Exposure and Risk of Abnormal Newborn Hearing Screen in Premature Infants
16
PubMed Central. Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review
17
PubMed. Comparative ototoxicity of bumetanide and furosemide when used in combination with kanamycin
18
PubMed. Effects of furosemide on distortion product otoacoustic emissions and on neuronal responses in the anteroventral cochlear nucleus
19
Frontiers in Neurology. Recent and Frequent Vertigo Attacks Produce Negative Findings on Furosemide-Loading Vestibular Evoked Myogenic Potential Testing in Meniere’s Disease